These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. Lanthanum carbonate for the treatment of hyperphosphatemia in CKD 5D: multicenter, double blind, randomized, controlled trial in mainland China. Xu J; Zhang YX; Yu XQ; Liu ZH; Wang LN; Chen JH; Fan YP; Ni ZH; Wang M; Yuan FH; Ding GH; Chen XM; Zhang AP; Mei CL BMC Nephrol; 2013 Feb; 14():29. PubMed ID: 23379590 [TBL] [Abstract][Full Text] [Related]
46. Effectiveness and safety of extended-release nicotinic acid for reducing serum phosphorus in hemodialysis patients. Aramwit P; Srisawadwong R; Supasyndh O J Nephrol; 2012; 25(3):354-62. PubMed ID: 21748722 [TBL] [Abstract][Full Text] [Related]
47. Initiation of Sevelamer and Mortality among Hemodialysis Patients Treated with Calcium-Based Phosphate Binders. Komaba H; Wang M; Taniguchi M; Yamamoto S; Nomura T; Schaubel DE; Smith AR; Zee J; Karaboyas A; Bieber B; Fukagawa M; Tentori F Clin J Am Soc Nephrol; 2017 Sep; 12(9):1489-1497. PubMed ID: 28724618 [TBL] [Abstract][Full Text] [Related]
48. Use of phosphate binders in chronic kidney disease. Ketteler M; Biggar PH Curr Opin Nephrol Hypertens; 2013 Jul; 22(4):413-20. PubMed ID: 23736841 [TBL] [Abstract][Full Text] [Related]
49. Efficacy and safety of nicotinamide in the management of hyperphosphatemia in pediatric patients on regular hemodialysis. El Borolossy R; El Wakeel LM; El Hakim I; Sabri N Pediatr Nephrol; 2016 Feb; 31(2):289-96. PubMed ID: 26420678 [TBL] [Abstract][Full Text] [Related]
51. One year efficacy and safety of lanthanum carbonate for hyperphosphatemia in Japanese chronic kidney disease patients undergoing hemodialysis. Shigematsu T; Ther Apher Dial; 2010 Feb; 14(1):12-9. PubMed ID: 20438515 [TBL] [Abstract][Full Text] [Related]
52. Effects of Tenapanor on Cytochrome P450-Mediated Drug-Drug Interactions. Johansson S; Rosenbaum DP; Ahlqvist M; Rollison H; Knutsson M; Stefansson B; Elebring M Clin Pharmacol Drug Dev; 2017 Sep; 6(5):466-475. PubMed ID: 28301096 [TBL] [Abstract][Full Text] [Related]
53. The economic impact of improving phosphate binder therapy adherence and attainment of guideline phosphorus goals in hemodialysis patients: a Medicare cost-offset model. Ramakrishnan K; Braunhofer P; Newsome B; Lubeck D; Wang S; Deuson J; Claxton AJ Adv Ther; 2014 Dec; 31(12):1272-86. PubMed ID: 25479935 [TBL] [Abstract][Full Text] [Related]
54. Treating hyperphosphatemia - current and advancing drugs. Ketteler M; Liangos O; Biggar PH Expert Opin Pharmacother; 2016 Oct; 17(14):1873-9. PubMed ID: 27643443 [TBL] [Abstract][Full Text] [Related]
55. Effect of gastric acid suppression with pantoprazole on the efficacy of calcium carbonate as a phosphate binder in haemodialysis patients. Cervelli MJ; Shaman A; Meade A; Carroll R; McDonald SP Nephrology (Carlton); 2012 Jul; 17(5):458-65. PubMed ID: 22471559 [TBL] [Abstract][Full Text] [Related]
56. Intensified treatment of hyperphosphatemia associated with reduction in parathyroid hormone in patients on maintenance hemodialysis. Chen L; He JX; Chen YY; Ling YS; Lin CH; Guan TJ Ren Fail; 2018 Nov; 40(1):15-21. PubMed ID: 29295646 [TBL] [Abstract][Full Text] [Related]
57. Long-term treatment of hyperphosphatemia with bixalomer in Japanese hemodialysis patients. Akizawa T; Kameoka C; Kaneko Y; Kawasaki S; Ther Apher Dial; 2013 Dec; 17(6):612-9. PubMed ID: 24330556 [TBL] [Abstract][Full Text] [Related]
58. The effect of oral niacinamide on plasma phosphorus levels in peritoneal dialysis patients. Young DO; Cheng SC; Delmez JA; Coyne DW Perit Dial Int; 2009; 29(5):562-7. PubMed ID: 19776051 [TBL] [Abstract][Full Text] [Related]